MedTrace Logo

A National Registry on Chinese Patients With Lymphangioleiomyomatosis

NCT03193892 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2021-09-24

No results posted yet for this study

Summary

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Conditions

  • Pulmonary Function

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • Guangzhou Institute of Respiratory Disease

    collaborator OTHER

  • Central South University

    collaborator OTHER

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Wuxi People's Hospital

    collaborator OTHER

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Fujian Provincial Hospital

    collaborator OTHER

  • Wuhan TongJi Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2026-10-01
Completion
2026-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193892 on ClinicalTrials.gov